CDMO and CRO selection should be evaluated as a regulatory and quality decision first, and a procurement decision second, using inspection history and oversight model design as the evaluative frame.
White Paper
Your CDMO Is Part of Your Regulatory Strategy

Related Resources
All Resources

post
How to Choose a Partner to Optimize INDs
Read More

post
Four Top Roadblocks to Successful IND Applications and How to Overcome Them
Read More

case-study
U.S. Based Independent Biotech Company Finds Success in Syner-G’s Capabilities in Manufacturing for Both Pre-Clinical and Clinical Trials Case Studies
Read More

post
Understanding Large Molecule Manufacturing: From Biologics to Market
Read More
Let's move from science to success.
Let’s Talk